Lymphoma

Researchers are testing a treatment called CD30 CAR-T cell therapy in adults with CD30-positive lymphoma that has returned or stopped responding to at least two prior treatments. The therapy involves collecting a patient's T cells, modifying them to recognize and attack CD30-posi…

Researchers are testing a personalized cell therapy called MT-601 in adults with Hodgkin or non-Hodgkin lymphoma that has come back or stopped responding to treatment. MT-601 is made from each participant's own T cells, which are trained in the lab to recognize several targets fo…

This early-stage trial is testing an experimental therapy that uses circular RNA to create CAR T cells directly inside the body, potentially eliminating the need to extract and modify cells in a lab. It is designed for adults with relapsed or refractory B-cell cancers, such as ce…

This trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…

This trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.

This study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…

This study tests whether adding daratumumab to standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare and aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the com…

This early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…

This phase 3 trial is testing whether adding the targeted drug obinutuzumab to standard radiotherapy improves outcomes for people with early-stage follicular lymphoma. About 190 participants will be randomly assigned to receive either radiotherapy alone or radiotherapy followed b…

This Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive suro…

This study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…

This early-stage trial is testing a new drug called TLN-121, alone or with other medicines, in about 180 people whose Non-Hodgkin Lymphoma has returned or stopped responding to prior treatments. The main goals are to check the drug's safety and how the body processes it, while al…

This Phase 3 study tests whether the experimental drug glofitamab works better than standard treatments (rituximab plus bendamustine or lenalidomide plus rituximab) for people with mantle cell lymphoma that has returned or not responded to prior therapy. About 182 participants wi…

This study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…

This study is testing a new type of immunotherapy called liso-cel (Breyanzi) as the first treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. The trial is for 65 adults who cannot have a stem cell transplant. Liso-cel is made from the patient's own…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a drug called CTO1681 in 54 adults with diffuse large B-cell lymphoma who are about to receive CAR-T therapy. The drug is taken three times daily for 15 days to prevent or reduce cytokine release syndrome, a potentially severe immune reaction. Researchers will mo…

This study tests a new CAR-T therapy made from donor cells, so it's ready to use without waiting for a patient's own cells to be modified. It targets two proteins on cancer cells to lower the chance of the cancer coming back. About 178 adults with relapsed or refractory B-cell ly…

This study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. …

This early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processe…

This phase 2 trial is testing whether a personalized cell therapy called CD22/CD19 CAR-T can help keep aggressive B-cell lymphoma in remission. Patients who achieved a complete response after standard second-line chemotherapy will receive a single infusion of their own geneticall…

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a drug called tislelizumab in people with newly diagnosed Hodgkin lymphoma who are not able to receive standard chemotherapy. The goal is to see if the drug can shrink or control the cancer. About 28 participants will take part in this phase 2 trial.

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This study tests whether fecal microbiota transplantation (FMT) can reduce gut-related side effects from antibiotics in 40 adults with B-cell lymphoma who are receiving standard CAR-T cell therapy. Participants will receive FMT alongside their cancer treatment to see if it improv…

This early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…

This study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.

This phase 2 trial tests the drug mosunetuzumab, alone or with zanubrutinib, in 152 adults with newly diagnosed follicular lymphoma who need treatment. The goal is to see how many patients achieve complete remission. Participants receive the drug as injections over several months…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This trial tests whether a drug called ATLG, used before a stem cell transplant, can help the immune system recover better and reduce viral infections compared to the standard drug ATG. The study involves adults with blood cancers like leukemia, lymphoma, or MDS who are receiving…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…

This study tests whether a prebiotic supplement called resistant starch can improve gut microbiome diversity in people with multiple myeloma or lymphoma after an autologous stem cell transplant. Thirty participants will take either the prebiotic or a placebo for about 10 days bef…

This study tests two different drugs—dexrazoxane and liposomal doxorubicin—to see which is safer and more effective at preventing heart failure in people with a type of lymphoma called DLBCL. All 60 participants will receive standard chemotherapy (R-CHOP or pola-R-CHP), and the g…

This study tests whether combining two drugs, mosunetuzumab and zanubrutinib, can safely control marginal zone lymphoma that has returned or stopped responding to prior treatment. About 36 adults with stage II–IV disease will receive the combination. The goal is to see how well t…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests whether a very low dose of radiation (4 Gy) can control marginal zone lymphoma, a slow-growing blood cancer. Participants first get the low dose, and if needed, a higher dose later. The goal is to see if this approach works with fewer side effects. About 50 adult…

This early-stage trial tests adding lenalidomide to standard chemotherapy (EPOCH) for adult T-cell leukemia-lymphoma, a rare and aggressive blood cancer linked to HTLV-1 infection. The main goal is to find the safest dose of lenalidomide when used with chemo. Up to 30 adults with…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This phase 2 trial is testing whether the drug loncastuximab tesirine (Lonca) can help patients with large B-cell lymphoma who had only a partial response after CAR T-cell therapy achieve a complete remission. About 30 adults will receive Lonca as a consolidation treatment. The s…

This study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participan…

This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…

This early-stage study tests an experimental drug called ELA026 in adults with T/NK cell blood cancers that have come back or not responded to prior treatments. The main goals are to check the drug's safety and find the right dose. About 84 participants will be enrolled across mu…

This expanded access protocol provides stem cell transplants for people with serious blood diseases like leukemia, bone marrow failure, or immune deficiencies who do not have a fully matched sibling donor. The donated stem cells are processed to remove certain immune cells (alpha…

This early-phase study tests a new treatment called BEAM-201 for children and young adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments. BEAM-201 uses donor-derived immune cells that are engin…

This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This early-phase trial is testing a new type of immune therapy called CD4CAR for people with T-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cel…

This study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30…

This early-phase trial is testing a new cell therapy called TBI-2001 for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to recognize and a…

This study looks at whether a lower dose of radiation can safely prevent cancer from returning in people with early-stage nasal-type NK/T-cell lymphoma who have already had a complete response to chemotherapy. Participants receive 45 Gy of radiation over five weeks, targeting the…

This study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors a…

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This early-phase study tests a personalized cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. The therapy uses the patient's own immune cells, modified to attack the cancer, and is made o…

This study compares two pneumococcal vaccination strategies in 160 adults with lymphoma who have had chemotherapy. One group gets two vaccines (Prevenar 13 followed by Pneumovax 23), while the other gets a single newer vaccine (Prevenar 20). Researchers will measure immune respon…

This study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the …

This study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how lo…

This study looks at whether a drug called dexrazoxane can help prevent heart damage in children and teens who have been treated for certain cancers like leukemia, lymphoma, and osteosarcoma. Researchers will measure heart function and blood markers in 420 survivors to see if dexr…

This phase 2 trial tests whether adding a short course of radiation to the drug glofitamab can help people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have large tumors. About 40 adults in China will receive glofitamab plus radiation. The main goal is to…

This early-phase study tests an experimental therapy called V001 Injection, which aims to create cancer-fighting cells directly inside the body. It is for people with advanced blood cancers or solid tumors that have not responded to standard treatments. The main goals are to chec…

This study tests a new type of immunotherapy called CD19/CD22 CAR-T cells as an early consolidation treatment for people with follicular lymphoma who still have some disease after standard chemotherapy. About 20 participants will receive a single infusion of their own modified im…

This pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This phase 2 trial is testing whether a combination of two drugs, venetoclax and rituximab, works better than standard chemotherapy for people with a rare blood cancer called Waldenström's macroglobulinemia who have not yet been treated. The study aims to see if this chemotherapy…

This phase II trial compares standard chemotherapy with newer drug combinations for people whose follicular lymphoma has returned or stopped responding to treatment. About 284 participants will receive either standard therapy or one of several experimental regimens, including a b…

This early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug move…

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …

This early-stage trial is testing a new oral drug called JBZ-001 in 25 adults with advanced solid tumors or certain blood cancers (like lymphoma) that have not responded to standard treatments. The drug works by blocking a protein cancer cells need to grow. The main goals are to …

This program provides early access to CTL019, a cell therapy that reprograms a patient's own immune cells to attack cancer. It is for people with lymphoma or leukemia who have no other treatment choices and cannot join a clinical trial. The goal is to offer a potential benefit wh…

This study tests the drug ruxolitinib in people with T or NK cell lymphoma that has come back or not responded to prior treatment. Ruxolitinib works by blocking a protein called JAK, which helps these cancer cells survive. The goal is to see if the drug can shrink tumors or contr…

This study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. The trial involves 20 adults with blood cancers like lymphoma, myeloma, or leukemia. Before ge…

This study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …

This study tests a drug called AVM0703, a very strong steroid, given as a one-time IV infusion. It aims to see if it is safe and can shrink tumors in people with certain blood cancers like lymphoma and leukemia. The trial will enroll 144 participants aged 12 and older.

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…

This phase 3 trial tests the drug duvelisib against two standard chemotherapy drugs (gemcitabine or bendamustine) in 124 people with a rare type of lymphoma (nodal T cell lymphoma with TFH phenotype) that has returned or not responded to prior treatment. The main goal is to see i…

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…

This early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…

This phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or…

This early study tests a new cell therapy called RGL-305 in 12 lymphoma patients who still have traces of cancer after standard treatment. The therapy is given through an IV over several cycles. The main goal is to check if it is safe and how the cells behave in the body, not yet…

This phase 2 trial is testing a new combination of chemotherapy, radiation, and immune-suppressing drugs for people aged 18-65 with blood cancers who need a stem cell transplant. The goal is to see if this regimen improves survival one year after transplant. About 209 participant…

This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …

This study tests whether new drug combinations can better prevent graft-versus-host disease (GVHD) in people with blood cancers who receive a stem cell transplant from a mismatched unrelated donor. About 358 participants will get either the standard GVHD prevention or one of two …

This phase 2 study is testing whether combining rituximab (an antibody) with venetoclax (a targeted pill) can improve outcomes for people with untreated marginal zone lymphoma. About 33 participants will receive the combination, and researchers will measure how many achieve a com…

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This study tests whether the drug epcoritamab can help people with follicular lymphoma who still have signs of cancer after their first round of chemoimmunotherapy. About 35 adults with advanced-stage disease will receive epcoritamab as a second treatment. The main goal is to see…

This study tests a drug called odronextamab in people with a slow-growing blood cancer (follicular lymphoma) who have not had treatment before and have low tumor burden. The goal is to see if the drug can shrink or eliminate the cancer. About 35 adults will receive the drug, and …

This study tests whether adding two newer drugs, glofitamab and polatuzumab, to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults with untreated CD20-positive lymphoma will receive the combination. The main…

This study tests whether adding the experimental drug capivasertib to a standard treatment (venetoclax plus low-intensity chemotherapy) is safe and effective for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma that has come back or not responded to prior …

This study tests a new way to make immune cells (called GRALE T cells) that are trained to attack cells infected with the Epstein-Barr virus (EBV), which is linked to some lymphomas. The trial includes people with Hodgkin or non-Hodgkin lymphoma, or related diseases, whose cancer…

This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had any prior treatment. The goal is to see if the drug can shrink or control the cancer. Participants take the drug by mouth and are monitored fo…

This phase 4 study is testing the safety and effectiveness of brentuximab vedotin (Adcetris) combined with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) in 124 Indian adults with untreated stage 3 or 4 classical Hodgkin lymphoma. Participants will receive the …

This expanded access program offers a stem cell transplant using donor cells that have been specially processed to remove certain immune cells, reducing the risk of graft-versus-host disease. It is for patients with serious blood disorders, immune deficiencies, or metabolic disea…

This phase 2 trial is testing a five-drug combination for people with untreated mantle cell lymphoma. The treatment includes standard chemotherapy plus newer targeted drugs. After initial therapy, some participants will receive an additional drug (sonrotoclax) to see if it helps …

This pilot study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can safely treat newly diagnosed primary central nervous system lymphoma. The trial will enroll 15 adults and primarily look for serious side effects, while also checkin…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This phase 2 trial is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in 45 people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo shrinks tumors and how safe it …

This study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…

This early-phase study tests whether stem cells from donated umbilical cord blood can safely help people whose blood counts stay dangerously low after CAR-T therapy. The trial will enroll 15 adults with leukemia, lymphoma, or myeloma. Participants receive weekly stem cell infusio…

This study tests whether a new type of radiation machine that uses MRI to guide treatment is safe and practical for people with gastric, breast, or other cancers. About 70 adults will receive radiation guided by real-time MRI, sometimes with chemotherapy. The goal is to see if th…

This study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The g…

This phase 2 trial tests whether combining two drugs, venetoclax and decitabine, can help adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to treatment. The study will enroll 28 participants and measure how many achieve complete remi…

This early-stage trial tests whether the experimental drug HCB101 is safe and can shrink tumors in people with advanced solid tumors or non-Hodgkin lymphoma that has come back or not responded to other treatments. About 80 adults aged 18 and older will receive the drug by IV. The…

This early-phase trial is testing a new drug called NB02 (posseltinib) in 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose a…

This trial tests whether giving children and teens with advanced solid tumors, brain tumors, or lymphomas drugs that match their tumor's genetic profile can help. About 90 participants will receive one of four drug combinations based on their tumor's molecular features. The goal …

This early study tests if a mild electrical pulse to a nerve in the ear (vagus nerve) can help protect the heart in people receiving strong chemotherapy for breast cancer or lymphoma. About 104 adults who recently started chemo and have extra heart risks will be randomly assigned…

This early-phase trial tests a new type of immune therapy called CD70-CAR T cells in children and young adults up to age 21 with blood cancers that have come back or not responded to treatment. The therapy involves taking the patient's own immune cells, engineering them to recogn…

This phase 2 trial tests whether adding IL-11 to the standard drug G-CSF helps blood cells recover faster after a stem cell transplant in people with multiple myeloma or lymphoma. About 224 adults will receive either the combination or G-CSF alone before their transplant. The goa…

This study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—for people with mantle cell lymphoma that has come back or hasn't been treated yet. The goal is to find the best dose and see how well it works at shrinking tumors. About 72 participants wil…

This study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…

This study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…

This study tests a combination of two drugs, ZG005 and gecacitinib, in 60 adults with relapsed or refractory lymphoma (cancer of the lymph system). The first part finds a safe dose; the second part checks if the combo shrinks tumors. Participants must have confirmed lymphoma that…

This study tests whether adding the drug eliglustat to CD30-targeted immunotherapy can make the treatment work better for people with CD30-positive lymphoma. About 40 adults who have already tried at least one other cancer treatment will receive either a CAR-T cell therapy or an …

This study tests a new treatment called GP350 CAR-T cells for people with blood cancers that are linked to the Epstein-Barr virus and have not responded to standard therapy. The treatment involves collecting a patient's own immune cells, modifying them to better target the cancer…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This study compares two types of blood thinners taken as pills (apixaban and rivaroxaban) against a standard daily injection (enoxaparin) to prevent dangerous blood clots in people with blood cancers like lymphoma, leukemia, and multiple myeloma. About 100 participants will be ra…

This pilot study is testing a new treatment called Anbal-cel for people with relapsed or refractory primary or secondary central nervous system lymphoma. Anbal-cel is a CAR-T cell therapy made from the patient's own immune cells. The study will enroll 12 participants to see if th…

This early-stage trial is testing a new type of immune cell therapy called supCD7 CART cells in 12 adults with relapsed or refractory CD7-positive blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia). The cells are designed to target and kill cancer cells that carry…

This study tests a combination of two drugs, pirtobrutinib (a pill) and rituximab (an infusion), in 50 adults newly diagnosed with a slow-growing form of mantle cell lymphoma. The goal is to see if this drug pair can shrink or control the cancer without the need for standard chem…

This pilot study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor, can clear minimal residual disease (tiny amounts of leftover cancer) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 participants who have a…

This early-stage trial tests a new treatment called CD7-targeted CAR-T cells for people with T-lymphoblastic leukemia or lymphoma that remains after a stem cell transplant. The therapy uses a patient's own or a donor's immune cells, modified to find and destroy cancer cells. The …

This study tests whether taking a postbiotic supplement (butyrate) for 7 days before colorectal cancer surgery can lower the chance of complications like infections or bowel issues. Researchers will compare complication rates in 164 adults who get the supplement versus those who …

This study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effect…

This study tests whether the drug maribavir can safely control cytomegalovirus (CMV) infections in people with multiple myeloma or lymphoma who are receiving bispecific antibody therapy. About 20 adults will take maribavir, and researchers will measure how well it lowers CMV leve…

This Phase 2 trial is testing a single infusion of axicabtagene ciloleucel, a CAR T-cell therapy, in 45 adults whose diffuse large B-cell lymphoma has returned more than a year after previous treatment. The main goal is to see how many patients have no signs of cancer on a PET/CT…

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…

This program offers extra stem cells from a half-matched family donor to patients who are getting a cord blood transplant for serious blood cancers or immune disorders. The goal is to help the bone marrow recover more quickly while the cord blood cells take over permanently. It i…

This early-phase study tests a new experimental drug called AN4005 in about 31 people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants take the drug by mouth twice …

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This early-phase trial is testing a new type of CAR-T cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The therapy uses a protein called BAFF to help th…

This early-stage trial tests a new treatment called Senza5 CART5 for people with a type of T cell lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to better target and attack cancer cells. The main goal …

This study looks at 100 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). Half will keep taking the BTKi alone, while the other half will add a second pill called venetoclax for one year. After …

This study is testing whether umbilical cord blood stem cells from unrelated donors can safely and effectively restore blood cell production in people with serious conditions like leukemia, immune deficiencies, and inherited blood disorders. The main goal is to see how quickly th…

This study compares immunoglobulin (given through a vein or under the skin) with antibiotics to see which better prevents severe infections in people with blood cancers like myeloma, lymphoma, or leukemia who have low antibody levels. About 900 adults will take part. The goal is …

This study compares two infection-prevention strategies in 900 people with blood cancers like myeloma and leukemia. One group gets an antibiotic (co-trimoxazole) daily, while another receives immunoglobulin infusions every few weeks. The goal is to see which approach better preve…

This study compares different ways to prevent infections in people with blood cancers like myeloma, leukemia, and lymphoma. About 900 participants will receive either daily antibiotics or immunoglobulin therapy, or a combination. The goal is to see which approach works best to ke…

This study looks at different ways to prevent serious infections in people with blood cancers like myeloma, lymphoma, and leukemia. About 900 participants will receive either antibiotics or immunoglobulin therapy to see which approach works best. The goal is to find safer and mor…

This study tests a specific order of antibiotics for cancer patients who develop fever due to low white blood cells (febrile neutropenia). Twenty adults with blood cancers will receive a carbapenem first, then add vancomycin or linezolid if fever persists, and finally an antifung…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This study tests whether using a simple early warning score (NEWS) to quickly move high-risk blood cancer patients to the ICU can reduce deaths and organ failure. Over 2,200 adults receiving intensive chemotherapy or stem cell transplants will take part across ten hospitals. Half…

This study tests a new approach for people with peripheral T-cell lymphoma that has come back or not responded to standard treatments. Researchers take a patient's own immune T-cells, modify them in the lab to recognize and attack cancer cells carrying the CD30 protein, and infus…

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …

This study tests whether temporarily stopping blood flow in the arm with a blood pressure cuff can protect the hearts of lymphoma patients receiving chemotherapy. The procedure, called remote ischemic preconditioning, is done before each chemo session. Researchers will compare he…

This early-stage trial is testing a new type of immune cell therapy called BCMA-CD19 cCAR T cells in 12 patients with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own modified immune cells to at…

This early-stage trial is testing a personalized vaccine made from a patient's own tumor tissue. The goal is to see if it is safe and can help the immune system recognize and attack advanced solid cancers. About 30 adults with advanced solid tumors who have already tried other tr…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This early-phase study is testing a new type of immune cell therapy called universal CD7 CAR-T (uCD7 CART) in people with relapsed or refractory acute myeloid leukemia (AML) or T-cell leukemia/lymphoma. The cells are designed to target and kill cancer cells that carry the CD7 pro…

This trial is investigating whether a new type of PET/CT scan that targets a protein called CD38 can detect multiple myeloma tumors more accurately than the standard FDG PET/CT scan. The study will enroll 100 adults with multiple myeloma or certain lymphomas, who will receive bot…

This study tests whether a special PET scan using a tracer called 68Ga-Pentixafor can better detect and predict the course of blood cancers like lymphoma, multiple myeloma, and leukemia. The tracer targets a protein on cancer cells, potentially offering clearer images than standa…

This study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…

This study compares whole-body MRI, PET/MR, and PET/CT scans to see which is best at finding tumors in children and young adults with solid tumors, lymphoma, or osteosarcoma. Researchers will check how many tumors each scan detects and measure their metabolic activity. The goal i…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study is building a large database of MRI scans from 3000 adults with malignant brain tumors (gliomas, metastases, lymphomas). Researchers will train an artificial intelligence system to automatically identify and classify these tumors. The goal is to improve non-invasive di…

This study tests a new type of ultrasound called super-resolution ultrasound (SRUS) to see if it can better tell the difference between benign (non-cancerous) and malignant (cancerous) swollen lymph nodes. About 779 adults with abnormal lymph nodes will receive an injection of ul…

This study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…

This study tests whether the drug mogamulizumab can prevent adult T-cell leukemia/lymphoma (ATL) in people infected with HTLV-1 who are at high risk. About 134 participants will receive low doses of the drug over several weeks. The goal is to see if it can reduce the virus levels…

Researchers are studying whether proton therapy is practical on a national scale and whether it reduces late side effects, such as second cancers and heart damage, compared with standard photon radiation. The trial enrolls adults with Hodgkin or non-Hodgkin lymphoma confined to t…

This trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…

This study looks at whether fasting for 24 hours before and after chemotherapy is safe and doable for people with Hodgkin or Diffuse Large B Cell Lymphoma. 40 participants will either fast or follow standard care, tracking side effects, diet, and quality of life. The goal is to s…

This study tests whether a tailored physical activity program can help older adults maintain thinking and memory after a stem cell transplant for blood cancers. Participants aged 60 and older will follow a progressive, light-to-moderate exercise plan with support from therapists …

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This study tests whether a mind-body resilience group program can help lymphoma survivors cope better after finishing treatment. Researchers will enroll 254 adults who are within two years of completing curative therapy. Participants will either receive enhanced usual care or joi…

This trial tests whether a specially designed website, called Mosaic, can help blood cancer patients who are about to undergo a stem cell transplant feel less distressed and have a better quality of life. Participants are randomly assigned to use either the Mosaic website or a st…

This study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…

This study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …

This study tests whether an AI-generated personalized question prompt list (GPT-QPL) can help people with lymphoma or multiple myeloma ask more useful questions during their outpatient appointments. Researchers will create tailored question lists for 40 patients using ChatGPT, th…

This pilot study is testing whether music therapy delivered over video calls is a practical way to help blood cancer survivors who have trouble with memory, attention, and thinking. Researchers will enroll 60 adults who have had lymphoma, leukemia, or myeloma. Participants will e…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study tests a digital app that connects young adults (ages 18-40) who have finished treatment for lymphoma, breast cancer, testicular cancer, or sarcoma. The app pairs them with trained peer navigators to help with challenges like symptoms, school, work, and relationships. R…

This study tests whether using CPAP or BiPAP breathing machines can reduce tumor movement during radiation therapy for lung cancer, esophageal cancer, or lymphoma. About 31 adults with advanced but treatable cancers will try these machines during treatment. The goal is to see if …

This pilot study is testing whether an AI-powered smartphone app called ASSIST can help people with breast cancer, lymphoma, or colorectal cancer manage symptoms while on systemic therapy. Sixty participants will either use the app for 12 weeks or receive standard care. The main …

This study tests whether adding a non-opioid painkiller (ketorolac) to standard opioid pain medication can reduce the amount of opioids needed after preventive femur surgery. The study includes 60 adults with bone lesions from cancer who are getting a metal rod placed in the thig…

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study tests whether a special palliative care program (called PEACE) can improve quality of life for people with blood cancers like lymphoma, leukemia, or multiple myeloma who are receiving adoptive cellular therapy (ACT). About 90 participants will be randomly assigned to e…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study tests whether a 12-week program of short exercise breaks (walking, cycling, resistance bands) can improve heart health and reduce chemotherapy side effects in 24 newly diagnosed lymphoma patients. Participants will use activity trackers and get coaching to interrupt lo…

This study tests whether live, group-based exercise classes held over Zoom can help cancer survivors increase their physical activity, improve fitness, and enhance quality of life. Researchers will randomly assign 300 cancer survivors to either live online classes or recorded exe…

This early-phase trial at Mayo Clinic is testing whether eating magnesium-rich foods and applying a magnesium lotion can help keep magnesium levels healthy in people with lymphoma. The study will enroll 60 adults who have or had lymphoma. Researchers will also check for side effe…

This study tests an 8-week virtual rehab program (CaRE@Home) for adults who finished cancer treatment for breast, colorectal, head and neck cancers, or lymphoma within the last two years. The goal is to see if the program reduces disability and improves physical function, anxiety…

This study tests whether the allergy drug loratadine can prevent bone pain caused by G-CSF, a medicine used to collect stem cells for transplant. About 78 adults with lymphoma or multiple myeloma will receive either loratadine or a placebo. The goal is to see if loratadine reduce…

This study tests a home-based telerehabilitation program for adults with lymphoma or myeloma who have received CAR-T cell therapy. Participants use a tablet or VR headset, along with a pulse oximeter and Fitbit, to follow personalized exercise and nutrition plans. The goal is to …

This study tests a digital health program called AYA STEPS for adolescent and young adult cancer survivors. The program uses video sessions and online materials to teach skills for managing symptoms like pain, fatigue, and emotional distress, and to encourage follow-up care. Rese…

This phase 3 trial tests whether a program called GEM-S (geriatric evaluation and management with survivorship health education) can improve physical function in older cancer survivors. About 668 participants who have completed chemotherapy for lymphoma or solid tumors will be ra…

This study tests whether a diet rich in whole grains, vegetables, fruit, and fatty fish can reduce persistent fatigue in lymphoma survivors. One hundred participants will receive either the special diet counseling or general health advice over 3 months. The goal is to see if the …

This study looks at whether a 12-week home exercise program with remote coaching can help lymphoma survivors improve their heart and lung fitness and stay active after cancer treatment. About 80 adults who finished chemotherapy for lymphoma will either exercise at home with remot…

This study tests a new program that gives blood cancer patients access to blood transfusions at home while they receive hospice care. The goal is to see if this improves their quality of life, mood, and reduces hospital visits near the end of life. The trial will include 700 adul…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…

This study follows up to 1,000 adults with certain slow-growing blood cancers (CLL, SLL, LPL, WM) to track how the diseases change over time. Participants have regular check-ups and blood draws every 6 to 24 months, and may also have optional biopsies or scans for research. No tr…

This study looks at how viruses change the environment around tumors in people with lymphoma, lung cancer, or anal cancer. Researchers will analyze blood and tumor samples from 254 patients to understand why some cancers resist treatment. The goal is to find new ways to make anti…

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This observational study is recruiting 300 active-duty service members and military beneficiaries diagnosed with B-cell non-Hodgkin lymphoma. Researchers want to understand how exposure to toxins, genetic differences, and immune system problems are linked to this cancer. Particip…

This study looks at how CAR T-cell therapy, a treatment for blood cancers, might affect thinking and memory in children and young adults aged 5 to 35. Researchers will test participants' memory, attention, and other thinking skills before and after treatment, over up to 3 years. …

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their values and shares that information with their doctors. The goal is to see if using PRIME leads to treatment decis…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study looks at how well vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia work in people with certain blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Researchers will measure immune responses through blood samples before and af…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study investigates the long-term heart and lung health of adults who survived childhood acute lymphoblastic leukemia (ALL) or lymphoma. Researchers use advanced MRI and other imaging to detect subtle damage from past chemotherapy, comparing survivors to healthy volunteers. T…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study collects extra blood and bone marrow samples from people receiving CAR-T cell therapy for lymphoma or acute lymphoblastic leukemia. The goal is to build a biobank that researchers can use to investigate why about half of patients do not respond to this treatment. Parti…

This study is testing whether a blood test can predict how well CAR-T cell therapy works in people with diffuse large B-cell lymphoma. Researchers will take blood samples before and after treatment to look for a specific immune cell activity called trogocytosis. The goal is to fi…

This study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…

This study follows about 50,000 people who survived childhood cancer (diagnosed before age 21 between 1970 and 1999) and 10,000 of their siblings. Researchers want to understand how cancer treatments like radiation, chemotherapy, and surgery affect health years later. By comparin…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This early-stage study explores whether exercise can improve the quality of immune cells collected from healthy donors for blood cancer treatments. Researchers will have healthy volunteers cycle, take a beta blocker or placebo, or receive a drug that mimics adrenaline, then analy…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…

This study looks at how a stem cell transplant changes a person's DNA and how that affects drug dosing. Researchers will collect blood, skin, hair, and other samples from 88 adults before and after transplant. The goal is to find the best way to test a patient's genes for safe an…

This study collects blood and tumor samples from 700 adults receiving approved CAR-T therapy for blood cancers. Researchers will analyze these samples to identify biological markers that predict whether the therapy will work or if the cancer will return. The goal is to improve fu…

This observational study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. Researchers will track how often infections occur, how severe they are, and what factors raise infection risk. The goal is to better …

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results an…

This study follows 270 young women treated for lymphoma with chemotherapy to see how their ovaries recover over 5 to 10 years. Researchers measure hormone levels and egg counts to understand long-term fertility and pregnancy rates. The goal is to help doctors give better advice o…

This study looks at whether a blood test that finds tiny bits of tumor DNA (called cfDNA) can help doctors see if lymphoma is still present after treatment. About 517 adults with diffuse large B-cell lymphoma will give blood samples before and after therapy. The goal is to see if…

This study follows 100 adults with blood cancers (like lymphoma or leukemia) who receive whole brain radiation. Researchers will test memory, thinking, and quality of life over time using MRI scans and questionnaires. The goal is to understand how radiation affects the brain, not…

This study is testing whether a new tool called xDRIVE, which combines artificial intelligence and tumor profiling, can quickly suggest personalized treatment options for cancer patients in Florida whose cancer has come back or not responded to standard treatments. The goal is to…

This study tests a 4-session virtual program called CHAT-S for young adult cancer survivors aged 26-39. The program aims to improve their understanding of health insurance, reduce financial burden, and help them get recommended follow-up cancer screenings. Researchers will track …

This study tests whether a special PET scan (18F FLT) can detect signs of leukemia or myeloma after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat blood cancers will get the scan before and after therapy. Researchers will compare the scan results with stan…

This study observes older patients (60+) receiving standard CAR-T therapy for blood cancers. Researchers track how treatment affects daily activities, thinking skills, and overall quality of life. No extra treatments are given—just careful monitoring to learn more about patient e…

This study is testing a new combination of blood tests, scans, and health checks to see if it can predict which lymphoma patients will respond well to CAR T cell therapy. Researchers will follow 50 patients with relapsed or hard-to-treat B-cell lymphoma who are already scheduled …

This study follows 475 women with breast cancer or lymphoma to understand how their treatments affect sexual function and fertility. Participants complete questionnaires and may optionally provide blood samples to measure ovarian health. The goal is to learn about these long-term…

This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…

This study looks at how services from Blood Cancer United (formerly The Leukemia & Lymphoma Society) affect people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will track 400 patients over time to see if the organization helps with access to care, quality …

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This early-phase trial is testing whether a special PET scan can track immune cells called CD8+ T cells in cancer patients before and after radiation therapy. The study includes 10 people with lymphoma or solid tumors that have spread. Researchers hope this imaging method could o…

This study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma by studying families where more than one person has the disease. Researchers will collect DNA and blood samples from up to 500 participants, including patients and th…

This study is testing whether a new blood test (PhasED-seq) can detect leftover cancer DNA in real time during standard chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL). For patients whose blood shows no cancer DNA halfway through treatment, doctors will sho…

This study is observing 2,000 lymphoma patients who also develop hemophagocytic lymphohistiocytosis (HLH), a severe immune overreaction. Researchers will collect data on which treatments patients receive and how they respond, aiming to identify factors that improve survival at 18…

This study looks at rare lymphomas that are hard to tell apart under the microscope—some look like Hodgkin lymphoma but lack a key marker (PAX5), making them similar to another type called anaplastic large cell lymphoma (ALCL). Researchers will analyze tissue samples from 60 adul…

This study is testing whether a quick, practical geriatric assessment—looking at mobility, memory, self-care, and nutrition—can predict severe side effects in patients 65 and older who are about to receive CAR-T cell or bispecific antibody therapy for blood cancers like multiple …

This study analyzes stored blood and tissue samples from 654 people with follicular lymphoma to learn how certain genetic changes affect the disease. Researchers are focusing on a gene called EZH2 and other biomarkers. The goal is to better understand the disease, not to test a n…

This study tests whether an AI-powered chatbot can help people with blood cancers like leukemia and lymphoma better understand clinical trials and feel more willing to join them. Researchers will compare patients who get standard education plus AI chatbot sessions to those who on…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study will analyze genetic material from stored tumor samples of 40 adults with advanced solid tumors or lymphoma. The goal is to see if molecular profiling can help identify more patients for early phase clinical trials. Researchers will track how many patients with a genet…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…

This study follows 120 adults with lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills, and perform brain MRIs and blood tests before and after treatment. The goal is to understand how CAR-T therapy may affect the brai…

This study tests whether a smartwatch combined with artificial intelligence can reliably detect early signs of heart damage in people who have been treated for lymphoma or sarcoma. Researchers will enroll 250 survivors and use mobile ECGs to monitor heart function over time. The …

This study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to…

This study looks at how cancer affects not just patients, but their entire family. Researchers will survey 240 Danish patients with breast, prostate, colorectal cancer, or lymphoma, along with their caregivers. They will measure family health, stress, depression, and quality of l…

This study is a registry that tracks patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on recovery, complications, and costs over time. The goal is to understand how high altitude affect…